• Tocilizumab manages adverse events following PD-1 blockade therapy

    7 days ago - By Healio

    CHICAGO - Tocilizumab appeared to be a viable therapeutic option for patients with lung cancer who experienced an immune-mediated adverse event following treatment with PD-1 checkpoint blockade, according to study results presented at International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology.Despite their clinical benefit, immune checkpoint inhibitors can be associated with a variety of immune-mediated adverse events.
    Read more ...